World of DTC Marketing

DECEMBER 22, 2020

81 percent of American adults have a smartphone, according to Pew Research but we must remember there is a huge difference between “health (wellness) apps and apps that focus on specific health conditions” The global mHealth app market is growing fast and expected to reach $111 billion by 2025. This is new to pharma.

Pharma 230

Pharma Doctors Patients Management 230

Fierce Pharma

SEPTEMBER 12, 2024

Gilead Sciences is no stranger to making history in HIV. | In a study of more than 3,000 participants, Gilead's twice-yearly lenacapavir delivered a 96% reduction in HIV infections compared with background HIV incidence.

331

331

Fierce Pharma

JUNE 12, 2023

market without a patent infringement challenge by early 2025 thanks to a new settlement. 21, 2025. Another biosimilar product copying Johnson & Johnson’s top-selling drug Stelara may enter the U.S. Following a deal with Amgen, J&J has granted Alvotech and Teva a license to launch their Stelara biosimilar no later than Feb.

Marketing 324

Marketing 324

Fierce Pharma

MAY 28, 2024

A recently announced $900 million restructuring drive is already making waves at Takeda, wi | From early July to March 2025, the Japanese drugmaker will cut 495 staffers at its Cambridge location and 146 in Lexington, Massachusetts. Takeda is the largest life sciences employer in the state.

344

344

Fierce Pharma

AUGUST 9, 2024

With Gilead's stated focus to grow in oncology, the company's recent quarterly updates have placed a heavy emphasis on its developments in the cancer space. | The HIV-focused drugmaker looks to position its long-acting Sunlenca as a prime PrEP option after the med aced a phase 3 study.

Marketing 299

Marketing 299

PharmaVoice

OCTOBER 1, 2024

Mark your calendars for the most important industry conferences in 2025.

Pharma 101

Pharma 101

Fierce Pharma

OCTOBER 29, 2024

Incyte’s blockbuster JAK inhibitor Jakafi has been driving the company’s sales for years now, with this quarter being no different. Meanwhile, the company also scrapped plans to expand its topical JAK Opzelura into two other skin disorders.

Sales 302

Sales 302

Fierce Pharma

JANUARY 3, 2024

As the J.P. Morgan Healthcare Conference kicked off in San Francisco, EY released its annual report on the industry's dealmaking firepower. | As the J.P. Morgan Healthcare Conference kicked off in San Francisco, EY released its annual report on the industry's dealmaking firepower.

Healthcare 312

Healthcare Healthcare Sales 312

Fierce Pharma

JUNE 5, 2024

billion in costs by the end of 2025, a company spokesperson said over email. . | Starting this month, BMS will begin the process of laying off around 863 employees in Lawrenceville, New Jersey, according to a Worker Adjustment and Retraining Notification (WARN) alert from the state. The move forms part of BMS’ campaign to shave off $1.5

321

321

Fierce Pharma

AUGUST 7, 2024

In its quarterly earnings presentation, the Danish company said that after discussions with the FDA, it has pulled its filing and expects to resubmit in early 2025. . | Novo Nordisk’s attempt to gain an approval to treat heart failure patients with its obesity drug Wegovy has been put on hold.

FDA 316

FDA Patients 316

Fierce Pharma

OCTOBER 31, 2024

billion restructuring initiative that runs through 2025 may not be the end of the company’s ongoing efficiency push. | Bristol Myers' $1.5 billion restructuring initiative that runs through 2025 may not be the end of the company's ongoing efficiency push. Bristol Myers’ $1.5

325

325

Fierce Pharma

OCTOBER 18, 2024

Integrated Patient Support Services, IQVIA | The 2025 Medicare Part D redesign will eliminate the “donut hole” and reduce out-of-pocket costs. Nancy McGee, VP & GM U.S. Patient Support Services, IQVIAJennifer Millard, VP U.S. Patient support is crucial for a smooth transition and better patient outcomes.

Patients 130

Patients 130

Fierce Pharma

AUGUST 19, 2024

With its rapid development of the Jynneos vaccine, Bavarian | After the WHO declared mpox a global health emergency for the second time in 25 months, Bavarian Nordic said it could ramp up manufacturing to supply 12 million doses of its Jynneos vaccine through 2025 to contain the virus in Africa.

Manufacturing 278

Manufacturing 278

pharmaphorum

JULY 8, 2022

That spend is due to reach of $3 billion by 2025, according to GlobalData analyst Kitty Whitney, who notes that there has been a steady stream of startups formed in the last three to four years to tap into the emerging AI market. The post Pharma’s spend on AI in drug discovery ‘could top $3bn by 2025’ appeared first on.

Marketing 131

Marketing Pharma Education Medicine 131

Fierce Pharma

NOVEMBER 1, 2023

But the new product will not launch until 2025 because of a settlement the companies made earlier this year, which delayed the launch in exchange for J&J dropping a patent infringement lawsuit. The FDA has signed off on Amgen’s biosimilar version of Johnson & Johnson’s autoimmune standout Stelara. |

FDA 314

FDA 314

Fierce Pharma

NOVEMBER 27, 2024

Before Exelexis’ Cabometyx can pass muster with the FDA in its hopeful neuroendocrine tumors indication next April, it will have to first face the agency’s Oncologic Drugs Advisory Committee ( | The agency's Oncologic Drugs Advisory Committee is set to discuss the treatment and its phase 3 CABINET study in March ahead of the FDA's planned (..)

FDA 246

FDA 246

Fierce Pharma

MARCH 21, 2024

The drugmaker's commitment will start by January 1, 2025, and follows similar moves by peers Boehringer Ingelheim and AstraZeneca. Amid congressional scrutiny on U.S. | Before the pledges, the companies—and Teva—caught Senate heat over high U.S. inhaler prices.

264

264

Fierce Pharma

APRIL 30, 2024

While an ongoing production expansion push for Eli Lilly's popular tirezeptide-based medicines Mounjaro and Zepbound should help out with perpetual supply strains later this year, the expected | While Eli Lilly's supply for Mounjaro and Zepbound is scheduled to increase during the second half of the year, demand is still expected to outpace (..)

Medicine 278

Medicine 278

Fierce Pharma

SEPTEMBER 11, 2023

Versions from Amgen, Teva and Alvotech are expected to launch in early 2025. . | The blockbuster inflammatory med's patents begin to expire this year, leaving biosimilar makers scrambling for a piece of the large market.

Marketing 298

Marketing 298

Fierce Pharma

AUGUST 26, 2024

When CVS Caremark removed AbbVie’s Humira from its national commercial formularies back in April, biosimilar prescriptions picked up at a whirlwind pace. Following CVS Caremark's lead, Cigna's pharmacy benefit manager unit will nix Humira from formularies in favor of Humira biosimilars from Boehringer Ingelheim, Teva and Sandoz.

Prescription 264

Prescription Management Leads 264

Fierce Pharma

AUGUST 19, 2024

. | The agency granted a broad regulatory exclusivity to rival United Therapeutics and its Tyvasvo DPI, leaving Liquidia's Yutrepia, which uses the same active drug, in FDA limbo until 2025.

FDA 264

FDA 264

Fierce Pharma

AUGUST 23, 2023

In October of last year, GSK laid out a plan to double its business in China by 2025, with much of that expansion dependent upon the succe | In October of last year, GSK laid out a plan to double its business in China by 2025, with much of that expansion dependent upon the success of shingles vaccine Shingrix.

246

246

Fierce Pharma

JUNE 10, 2024

The FDA assigned the subcutaneous Leqembi application a Prescription Drug User Fee Act decision date of January 25, 2025. About a month after Eisai initiated a rolling FDA application for its subcutaneous form of Leqembi, the U.S. agency has accepted the filing. |

FDA 241

FDA Prescription 241

Fierce Pharma

OCTOBER 7, 2024

GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | The long-acting HIV PrEP maker pledged to make at least 2 million more doses available for low-and middle-income countries in 2025 and 2026.

Healthcare 246

Healthcare Healthcare 246

Fierce Pharma

OCTOBER 24, 2023

The company expects a decision in the first quarter of next year and is making plans to launch the treatment in the 2024-2025 flu season. The FDA has accepted AZ’s supplemental biologics license application (sBLA) for self-administered FluMist Qudrivalent.

FDA 290

FDA Marketing 290

Fierce Pharma

DECEMBER 17, 2024

Jazz aims to complete its search for a CEO successor by the end of 2025, after which Cozadd will stay on board as the drugmaker's board chair. . | Current helmsman Bruce Cozadd plans to retire from his role at Jazz Pharmaceuticals in the next 12 months, the company said Monday.

Pharmaceutical 256

Pharmaceutical 256

Fierce Pharma

JUNE 29, 2023

Much of that momentum hinges on Sanofi’s pipeline, where the company is targeting an “accelerated pace of innovation” in a bid to launch at least five phase 3 vaccine programs by 2025.

Sales 264

Sales 264

Fierce Pharma

JULY 10, 2023

After a Delaware federal court ruled a Novartis combination patent on big-selling cardiovascular drug Entresto is invalid, the company pledged to continue its efforts to block generics with an appe | After a Delaware district court ruled a 2025 Entresto combination patent is invalid, Novartis will head to the U.S.

269

269

MedCity News

NOVEMBER 19, 2024

The post Managing the Specialty Drug Cost Challenge: Is Your Pharmacy Benefits Strategy Ready for 2025? What concrete strategies should employers pursue to control rising costs while ensuring the best member experience and clinical outcomes? appeared first on MedCity News.

Management 119

Management Pharmaceutical Biopharma Pharma 119

Eversana Intouch

NOVEMBER 18, 2024

These three trends are digitally driven, overlapping and profoundly changing pharma marketing. In this report, 15 of our experts examine the current impact of each of these three forces, predict how you’ll see their effects in 2025 and give recommendations for how to make these market forces work for you. This isn’t about buzzwords.

Marketing 59

Marketing Pharma Competition Patients 59

Pharma Marketing Network

DECEMBER 4, 2024

As we approach 2025, emerging trends are reshaping how the industry engages with patients and healthcare providers. With advancements in technology, increasing competition, and changing patient expectations, pharma marketers need to stay ahead of the curve. For further reading on AI applications, visit Pharma Marketing.

Marketing 52

Marketing Pharma Media Education 52

European Pharmaceutical Review

DECEMBER 11, 2024

LOG Pharma Primary Packaging is set to present its new barrier eco line at Pharmapack Europe 2025. The innovative design integrates pharma-grade HEALTH + resins with superior gas barrier properties. Pharmapack Europe 2025 The innovative design integrates pharma-grade HEALTH + resins with superior gas barrier properties.

Pharma 59

Pharma Government Competition Pharmaceutical 59

Pharma Marketing Network

NOVEMBER 1, 2024

The world of pharma marketing is changing rapidly, and 2025 will be no exception. For pharma marketing executives, adapting to these shifts isn’t just about keeping up—it’s about staying ahead. So, what will be the top challenges in 2025, and how can pharma marketers tackle them?

Marketing 52

Marketing Pharma Ethics Healthcare Provider 52

Pharmaceutical Commerce

AUGUST 13, 2024

The latest news for pharma industry insiders.

Pharma 105

Pharma 105

Pharmaceutical Technology

DECEMBER 20, 2024

The UK's DHSC has announced its anticipated 2025 headline payback rate for new medicines under the 20242028 VPAG.

Government 59

Government Medicine Pharma Marketing 59

MedCity News

DECEMBER 18, 2024

The post Future Trends for Clinical Trials in 2025 and Beyond appeared first on MedCity News. Four key predictions for the future of clinical trials, examining how these changes will revolutionize the speed, efficiency, and reliability of bringing life-saving treatments to market.

Marketing 66

Marketing Biopharma Pharma 66

PharmExec

OCTOBER 22, 2024

In this part of her video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member identifies marketing trends you expect to be big right away in 2025.

Marketing 52

Marketing Pharma Pharmaceutical 52